Pirenzepine

An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Also Known As:

Networked: 520 relevant articles (76 outcomes, 110 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Dean, Brian: 8 articles (01/2017 - 05/2007)
2.	Scarr, Elizabeth: 8 articles (01/2017 - 05/2007)
3.	Dean, B: 6 articles (11/2009 - 03/2000)
4.	McBrien, Neville A: 4 articles (08/2012 - 01/2002)
5.	Huang, Xu-Feng: 4 articles (05/2012 - 03/2004)
6.	Li, Pengmei: 3 articles (07/2021 - 08/2005)
7.	Tu, Jiasheng: 3 articles (07/2021 - 08/2005)
8.	Calcutt, Nigel A: 3 articles (01/2021 - 02/2017)
9.	Walline, Jeffrey J: 3 articles (01/2016 - 01/2003)
10.	Scarr, E: 3 articles (11/2009 - 01/2002)

Related Diseases

1.	Duodenal Ulcer (Curling's Ulcer) 11/25/1987 - "Pirenzepine 100 mg administered at night is therefore an effective treatment for gastric and duodenal ulcers." 01/01/1982 - "Pirenzepine appears to be an effective drug for the short-term treatment of duodenal ulcer. " 01/01/1982 - "Pirenzepine (100 mg/day for six weeks) should be an effective and safe treatment for duodenal ulcers." 08/01/1986 - "The efficacy of pirenzepine in duodenal ulcer healing." 01/01/1987 - "A study on the prevention of duodenal ulcer recurrence with pirenzepine."
2.	Myopia 04/05/2005 - "The significant reduction in myopia in 2% and 4% pirenzepine treated animals was caused by significantly less vitreous chamber elongation and axial elongation of the deprived eyes [2% group: (0.009+/-0.052) mm, 4% group: (0.006+/-0.078) mm] when compared with untreated, saline treated or 1% pirenzepine treated guinea pigs (0.057+/-0.056) mm, (0.064+/-0.053) mm and (0.033+/-0.035) mm, respectively]. " 09/01/1995 - "Daily subconjunctival injection of pirenzepine was significantly less effective in preventing form deprivation myopia. " 08/01/2008 - "To evaluate if the safety and efficacy of the relatively selective M1-antagonist, pirenzepine, in slowing the progression of myopia in children is sustained over a 2-year period. " 09/01/1995 - "Pirenzepine was effective in preventing the axial elongation associated with experimental myopia in a dose dependent manner and via a functional not toxic mechanism." 11/01/2004 - "Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: a 1-year, multicenter, double-masked, placebo-controlled parallel study."
3.	Ulcer 04/01/1993 - "Pirenzepine can be regarded as an effective agent for the control of postoperative gastric hypersecretion and possibly a good prophylactic for postoperative stress ulcers." 01/01/1991 - "Pirenzepine 1, 2.5 and 5 mg/kg every 2 h all caused a significant reduction in mean total ulcer length (p less than 0.01) compared to controls. " 08/01/1987 - "Thus pirenzepine is effective in ulcer prevention even if administered in an interrupted manner." 05/12/1986 - "In an endoscopic controlled trial the effectiveness of pirenzepine in preventing stress ulcer in high risk patients for surgical operation was studied. " 06/01/1980 - "[Stress-ulcer prevention with pirenzepine-a controlled study]."
4.	Peptic Ulcer (Peptic Ulcers) 01/01/1980 - "These results suggest that pirenzepine might be especially useful in the treatment of those patients with peptic ulcer who have high proteolytic activity of their gastric juice." 11/01/1985 - "Although pirenzepine appears effective in peptic ulcer, the results obtained in different centers have not been uniform. " 01/01/1986 - "A modified x-ray method was applied in 41 patients with peptic ulcer of the duodenum to study twice (without gastrozepin intake and after its administration in courses) the rate of evacuation from the gastrointestinal tract (GIT) of radiographic contrast capsules taken with a trial meal. " 11/15/1983 - "From the results of the present investigation it is concluded that Pirenzepine has a more beneficial effect in the treatment of peptic ulcers than placebo as observed in other studies." 11/08/1982 - "[Multicenter controlled clinical studies on the effectiveness of pirenzepin in the treatment of peptic ulcer]."
5.	Stomach Ulcer (Gastric Ulcer) 11/01/1988 - "In a double-blind randomised four-center trial 43 patients with gastric ulcer (20 men, 23 women; mean age 52.2 years) were treated with either pirenzepine (P) 50 mg b.i.d. " 09/30/1982 - "In two studies the beneficial effect of Pirenzepine in the treatment of peptic duodenal and gastric ulcers was investigated in 1686 outpatients. " 01/01/1982 - "In 4 randomized double-blind placebo-controlled studies in which 84 patients with gastric ulcer were admitted, the healing rates were similar (50% when daily dosage of pirenzepine was 75 mg or less, 72% when the dosage ranged from 100 to 150 mg). " 11/01/1988 - "In gastric ulcer, treatment with pirenzepine 50 mg b.i.d. " 11/01/1988 - "The intragastric milieu during gastric ulcer treatment with pirenzepine 50 mg b.i.d. "

Related Drugs and Biologics

1.	Cimetidine (Biomet)
2.	Sucralfate (Carafate)
3.	Muscarinic Antagonists
4.	Atropine
5.	Ranitidine (Zantac)
6.	Cholinergic Agents (Cholinergics)
7.	Antacids
8.	Cholinergic Antagonists (Anticholinergics)
9.	Famotidine (Pepcid)
10.	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)

Related Therapies and Procedures

1.	Therapeutics
2.	Critical Care (Surgical Intensive Care)
3.	Lenses
4.	Drug Therapy (Chemotherapy)
5.	Subcutaneous Injections